达格列净:治疗2型糖尿病的新可能性

Future Prescriber Pub Date : 2012-01-03 DOI:10.1002/fps.86

Stephen Bain MA, MD, FRCP

{"title":"达格列净:治疗2型糖尿病的新可能性","authors":"Stephen Bain MA, MD, FRCP","doi":"10.1002/fps.86","DOIUrl":null,"url":null,"abstract":"Dapagliflozin is a new sodium-glucose transporter protein inhibitor under development for the treatment of type 2 diabetes mellitus. In this Drug profile, Professor Stephen Bain outlines why new treatments are needed, and considers the drug's efficacy and tolerability in clinical trials, to date, as well as its potential place in management. Copyright © 2011 John Wiley & Sons, Ltd.","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"12 4","pages":"14-16"},"PeriodicalIF":0.0000,"publicationDate":"2012-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.86","citationCount":"0","resultStr":"{\"title\":\"Dapagliflozin: a new possibility for managing type 2 diabetes\",\"authors\":\"Stephen Bain MA, MD, FRCP\",\"doi\":\"10.1002/fps.86\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Dapagliflozin is a new sodium-glucose transporter protein inhibitor under development for the treatment of type 2 diabetes mellitus. In this Drug profile, Professor Stephen Bain outlines why new treatments are needed, and considers the drug's efficacy and tolerability in clinical trials, to date, as well as its potential place in management. Copyright © 2011 John Wiley & Sons, Ltd.\",\"PeriodicalId\":100566,\"journal\":{\"name\":\"Future Prescriber\",\"volume\":\"12 4\",\"pages\":\"14-16\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-01-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/fps.86\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/fps.86\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.86","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Dapagliflozin: a new possibility for managing type 2 diabetes

Dapagliflozin is a new sodium-glucose transporter protein inhibitor under development for the treatment of type 2 diabetes mellitus. In this Drug profile, Professor Stephen Bain outlines why new treatments are needed, and considers the drug's efficacy and tolerability in clinical trials, to date, as well as its potential place in management. Copyright © 2011 John Wiley & Sons, Ltd.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future Prescriber

自引率

0.00%

发文量